BIO 2026: Former FDA staff question agency’s “radical transparency” approach - Pharmaceutical Technology

Former FDA employees discussed whether the agency’s commitment to openness risks creating a lack of clarity on official policies. Former FDA employees discussed whether the agency’s commitment to openness risks creating a lack of clarity on official policies. At the 2026 BIO International Convention, a panel of former FDA staffers discussed whether a “radical transparency” approach has in fact, made FDA policy less clear. Credit: Frankie Fattorini/GlobalData The US Food and Drug Administration (FDA)’s “radical transparency” approach may have provided a more direct method, but it has also meant lax standards around information disclosed in policy announcements, casting questions on…

Source: Pharmaceutical Technology